Allergy Rhinitis - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for allergy rhinitis including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration, by territory, therapeutic modality, and target.

Overview of the drug development pipeline for allergy rhinitis   

Allergy rhinitis is also termed as hay fever. Allergy rhinitis is consequent of an allergy response of the body to certain type of allergens. Pollen is one of the most common allergens in seasonal allergy rhinitis. External factors such as cigarette smoke, chemicals, humidity, air pollution, and wind, are responsible for increasing or triggering the condition. Patients suffering from allergy rhinitis suffer from complications such as inability to sleep, frequent ear infection and headaches, and development or worsening symptoms of asthma. This allergy is consequent in symptoms such as sneezing and a runny nose, stuffy and itchy nose, coughing, frequent headaches, itchy and watery eyes, and sore or scratchy throat. Technavio’s market research analysts reported that as per CDC in 2016, around 6.5% population above 18 years and 7.5% population below 18 years have been diagnosed with hay fever in the US.  

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the Phase III drug development stage. Our market research analysts have also identified that amount of drug molecules under the phase II and pre-clinical drug development stage. The pipeline landscape in the pipeline analysis report also mentions the same percentage of drug development molecules that are in the phase I stage, discovery stage, and pre-registration stage. 

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of allergy rhinitis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• GLENMARK
• HAL ALLERGY
• IMMUNOMIC THERAPEUTICS  

Therapeutic assessment of the drug development pipeline for allergy rhinitis by route of administration

• Subcutaneous
• Intranasal
• Sublingual
• Intradermal
• Intravenous

The subcutaneous route of administration (ROA) involves the administration of drug substances into the subcutis. It has been observed that a significant share of total therapeutics for allergy rhinitis are being developed for subcutaneous administration.     

Therapeutic assessment of the drug development pipeline for allergy rhinitis by therapeutic modality

• Small molecules
• Biologicals  
• Vaccine
• Monoclonal antibody

According to this pipeline analysis report, majority of the molecules that are currently in the drug development pipeline for allergy rhinitis are being developed as biological molecules. These molecules are large molecules, including carbohydrates, nucleic acids, and proteins.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for allergy rhinitis?
• What are the companies that are currently involved in the development of drug development molecules for allergy rhinitis?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.